CN101868233A - 与血清素双重作用化合物有关的组合疗法 - Google Patents

与血清素双重作用化合物有关的组合疗法 Download PDF

Info

Publication number
CN101868233A
CN101868233A CN200880118145A CN200880118145A CN101868233A CN 101868233 A CN101868233 A CN 101868233A CN 200880118145 A CN200880118145 A CN 200880118145A CN 200880118145 A CN200880118145 A CN 200880118145A CN 101868233 A CN101868233 A CN 101868233A
Authority
CN
China
Prior art keywords
htp
compositions
indol
amine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880118145A
Other languages
English (en)
Chinese (zh)
Inventor
C·S·莫里洛
T·D·沃林斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN101868233A publication Critical patent/CN101868233A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880118145A 2007-09-24 2008-09-24 与血清素双重作用化合物有关的组合疗法 Pending CN101868233A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97459507P 2007-09-24 2007-09-24
US60/974,595 2007-09-24
PCT/US2008/077435 WO2009042632A2 (en) 2007-09-24 2008-09-24 Combination therapy related to serotonin dual action compounds

Publications (1)

Publication Number Publication Date
CN101868233A true CN101868233A (zh) 2010-10-20

Family

ID=40512095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880118145A Pending CN101868233A (zh) 2007-09-24 2008-09-24 与血清素双重作用化合物有关的组合疗法

Country Status (6)

Country Link
US (1) US20100286226A1 (enExample)
EP (1) EP2205238A4 (enExample)
JP (1) JP2010540461A (enExample)
CN (1) CN101868233A (enExample)
CA (1) CA2700199A1 (enExample)
WO (1) WO2009042632A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107165A1 (en) * 2006-03-22 2007-09-27 H. Lundbeck A/S Method for identifying compounds for the treatment of depression
ES2703255T3 (es) * 2010-10-22 2019-03-07 Univ Duke Formulaciones de liberación lenta de 5-hidroxitriptófano como un complemento para terapias pro-serotoninérgicas
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932652A (en) * 1972-06-30 1976-01-13 Hoffmann-La Roche Inc. Antidepressant compositions
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
US4413012A (en) * 1981-06-01 1983-11-01 Merrell Toraude Et Compagnie Method for treating depression
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US20020147153A1 (en) * 2001-02-14 2002-10-10 Functional Foods, Inc. Nutritional supplement to alleviate symptoms associated with reduced levels of serotonin
US20040197377A1 (en) * 2003-04-03 2004-10-07 Thompson Marshall Anlauf 5-HTP composition
DK1701940T3 (da) * 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
WO2005112906A2 (en) * 2004-05-21 2005-12-01 Duke University Method for augmenting the effects of serotonin reuptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US20070213370A1 (en) * 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
US20070117844A1 (en) * 2005-11-18 2007-05-24 Morillo Connie S 5-HTP combination therapy
WO2007107165A1 (en) * 2006-03-22 2007-09-27 H. Lundbeck A/S Method for identifying compounds for the treatment of depression

Also Published As

Publication number Publication date
CA2700199A1 (en) 2009-04-02
EP2205238A2 (en) 2010-07-14
JP2010540461A (ja) 2010-12-24
WO2009042632A2 (en) 2009-04-02
EP2205238A4 (en) 2010-10-06
WO2009042632A3 (en) 2009-05-14
US20100286226A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
Carroll et al. Development of κ opioid receptor antagonists
Grasshoff et al. Anaesthetic drugs: linking molecular actions to clinical effects
CA2333024C (en) Method for the treatment of insomnia
SK13952002A3 (sk) Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
CN101242821A (zh) 肽类化合物用于治疗肌肉痛的新用途
US20120258984A1 (en) 5-htp combination therapy
TW200843763A (en) 5-HTP combination therapy
CN101868233A (zh) 与血清素双重作用化合物有关的组合疗法
JP2005508872A5 (enExample)
Popik et al. Pharmacological profile of the “triple” monoamine neurotransmitter uptake inhibitor, DOV 102,677
PT759299E (pt) Potenciacao da resposta de serotonina
McFarthing et al. Clinical trial highlights–dyskinesia
AU2005200619A1 (en) Method for the treatment of incontinence
CA2528312A1 (en) Methods of managing the symptoms of premenstrual syndrome
CN1136921A (zh) 治疗阿耳茨海默氏病的药剂
ES2323646T3 (es) Uso de derivados de pirrol contra la ansiedad.
de Filippis et al. Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report.
US6680343B1 (en) Treatment of renal colic with GABA analogs
Du et al. Clinically relevant concentrations of ketamine inhibit osteoclast formation in vitro in mouse bone marrow cultures
JP2010526804A (ja) ５−ｈｔｐ併用療法
KR20080013853A (ko) 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
Malin et al. Escitalopram: better treatment for depression is through the looking glass
TW458774B (en) Antiemetic pharmaceutical compositions
HK1134241A (en) 5-htp combination therapy
Palmer et al. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101020